Trial · NCT02008292
Acetylcholine, Tobacco Smoking, Genes and Nicotinic Receptors
NCT02008292, Not applicable, Completed, Yale University; results first posted 2023-02-06
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Acetylcholine, Tobacco Smoking, Genes and Nicotinic Receptors. Trials, record NCT02008292. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02008292
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Acetylcholine, Tobacco Smoking, Genes and Nicotinic Receptors
- NCT number
- NCT02008292
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 80 participants, actual
- Lead sponsor
- Yale University
- Conditions
- Smoking, Schizophrenia
- Interventions
- Physostigmine
- First posted
- 2013-12-11
- Last updated
- 2023-10-25
- Results first posted
- 2023-02-06
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Acetylcholine (ACh) Levels After Physostigmine Administration as Confirmed by PET Images. | first 150 minute scan at baseline, second 150 minute scan start 10 minutes post physostigmine administration | PET images will be obtained in healthy controls and smoker subjects after physostigmine administration. Change in ACh levels will be determined by change in binding potential of Norchloro-fluoro-homoepibatidine (NCFHEB) |
| Primary | Change in Dopamine (DA) Levels After Amphetamine Administration as Confirmed by PET Images. | first 120 min scan at baseline, second 120 scan 2.5 hours after amphetamine administration | PET images will be obtained in all subjects after amphetamine administration. Change in DA levels will be determined by change in binding potential of PHNO, a selective dopamine D2 receptor agonist. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in Acetylcholine (ACh) Levels After Physostigmine Administration as Confirmed by PET Images. | first 150 minute scan at baseline, second 150 minute scan start 10 minutes post physostigmine administration | 66 of 80 participants were analyzed in primary study as 14 had signed consent but did not fully complete aim (i.e. Medical DQ by MD prior to drug administration or Relapse in smoking cessation by participant or medical aline failure, participant unable reschedule. For primary measure we only included participants that voluntarily completed both primary measures successfully. | percentage of change | MEAN |
| PRIMARY | Change in Dopamine (DA) Levels After Amphetamine Administration as Confirmed by PET Images. | first 120 min scan at baseline, second 120 scan 2.5 hours after amphetamine administration | 66 of 80 participants were analyzed in primary study as 14 had signed consent but did not fully complete aim (i.e. Medical DQ by MD prior to drug administration or Relapse in smoking cessation by participant or medical aline failure, participant unable reschedule. For primary measure we only included participants that voluntarily completed both primary measures successfully. | percentage of change | MEAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Acetylcholine (ACh) Levels After Physostigmine Administration as Confirmed by PET Images. | ACH Levels in Healthy Controls After Physostigmine Administration | 5.9 | Standard Deviation 6.5 | percentage of change | |
| Change in Acetylcholine (ACh) Levels After Physostigmine Administration as Confirmed by PET Images. | ACH Levels in Smokers After Physostigmine Administration | 4.3 | Standard Deviation 8.4 | percentage of change | |
| Change in Dopamine (DA) Levels After Amphetamine Administration as Confirmed by PET Images. | Healthy Controls After Dextroamphetamine | 26.5 | Standard Deviation 6.5 | percentage of change | |
| Change in Dopamine (DA) Levels After Amphetamine Administration as Confirmed by PET Images. | Healthy Smoker After Dextroamphetamine | 19.6 | Standard Deviation 10 | percentage of change |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Healthy Controls for 1210010989 | 43 | |
| Overall Study | STARTED | Healthy Smoker Controls for 1210010989 | 37 | |
| Overall Study | COMPLETED | Healthy Controls for 1210010989 | 43 | |
| Overall Study | COMPLETED | Healthy Smoker Controls for 1210010989 | 37 | |
| Overall Study | NOT COMPLETED | Healthy Controls for 1210010989 | 0 | |
| Overall Study | NOT COMPLETED | Healthy Smoker Controls for 1210010989 | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Healthy Controls for 1210010989 | 0 | 43 |
| Total, all-cause mortality | Healthy Smoker Controls for 1210010989 | 0 | 37 |
| Total, other adverse events | Healthy Controls for 1210010989 | 0 | 43 |
| Total, other adverse events | Healthy Smoker Controls for 1210010989 | 0 | 37 |
| Total, serious adverse events | Healthy Controls for 1210010989 | 0 | 43 |
| Total, serious adverse events | Healthy Smoker Controls for 1210010989 | 0 | 37 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants3
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|---|---|---|---|---|---|
| K23DA045957 | Understanding Factors that Influence Electronic Cigarette Nicotine Delivery Through PET Imaging of Beta-2 Nicotinic Acetylcholine Receptors | BALDASSARRI, STEPHEN | YALE UNIVERSITY | NATIONAL INSTITUTE ON DRUG ABUSE | 2018 to 2022 | NIH RePORTER |
| R01DA038832 | Imaging Molecular Mechanisms of Tobacco Smoking Withdrawal | COSGROVE, KELLY P. | YALE UNIVERSITY | NATIONAL INSTITUTE ON DRUG ABUSE | 2016 to 2021 | NIH RePORTER |
| R01DA015577 | Tobacco Smoking, Genes & Nicotinic Receptors | COSGROVE, KELLY P. | YALE UNIVERSITY | NATIONAL INSTITUTE ON DRUG ABUSE | 2004 to 2013 | NIH RePORTER |
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Healthy Controls for 1210010989 vs Healthy Smoker Controls for 1210010989: deaths from any cause | Trial comparisons |
| Healthy Controls for 1210010989 vs Healthy Smoker Controls for 1210010989: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02008292
GET https://conductscience.org/api/trials/v1/NCT02008292/registered